Advertisement
Canada markets open in 5 hours 7 minutes

  • S&P/TSX

    22,265.05
    -108.35 (-0.48%)
     

  • S&P 500

    5,306.04
    +1.32 (+0.02%)
     

  • DOW

    38,852.86
    -216.74 (-0.55%)
     

  • CAD/USD

    0.7322
    -0.0007 (-0.10%)
     

  • CRUDE OIL

    80.49
    +0.66 (+0.83%)
     

  • Bitcoin CAD

    92,501.48
    -144.41 (-0.16%)
     

  • CMC Crypto 200

    1,460.62
    -24.08 (-1.62%)
     

  • GOLD FUTURES

    2,351.80
    -4.70 (-0.20%)
     

  • RUSSELL 2000

    2,066.85
    -2.82 (-0.14%)
     

  • 10-Yr Bond

    4.5420
    +0.0750 (+1.68%)
     

  • NASDAQ futures

    18,832.25
    -108.25 (-0.57%)
     

  • VOLATILITY

    14.01
    +1.09 (+8.44%)
     

  • FTSE

    8,235.77
    -18.41 (-0.22%)
     

  • NIKKEI 225

    38,556.87
    -298.50 (-0.77%)
     

  • CAD/EUR

    0.6753
    +0.0006 (+0.09%)
     

Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings

Zacks Equity Research
·2 min read

Deciphera Pharmaceuticals, Inc. (DCPH) reported $45 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 34.5%. EPS of -$0.52 for the same period compares to -$0.60 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $45.99 million, representing a surprise of -2.15%. The company delivered an EPS surprise of +5.45%, with the consensus EPS estimate being -$0.55.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

ADVERTISEMENT

Here is how Deciphera Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Product revenues, net- Rest of world: $10.71 million versus $10.77 million estimated by two analysts on average.

  • Product revenues, net- U.S. $31.84 million versus $33.68 million estimated by two analysts on average.

  • Collaboration revenues: $2.45 million versus the seven-analyst average estimate of $1.24 million.

  • Product revenues, net: $42.55 million versus the seven-analyst average estimate of $44.75 million. The reported number represents a year-over-year change of +28.1%.

View all Key Company Metrics for Deciphera Pharmaceuticals here>>>

Shares of Deciphera Pharmaceuticals have returned +63.5% over the past month versus the Zacks S&P 500 composite's +0.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research